Next Generation Immunotherapies


GEMoaB aspires to become a leading, fully integrated biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of next generation immunotherapies for patients in underserved cancer indications.


We are hiring!


GEMoaB develops next generation immunotherapies against hard-to-treat blood and solid tumor cancers


GEMoaB GmbH is a privately-owned, clinical-stage biopharmaceutical company based in Dresden, Germany. GEMoaB has a broad pipeline of next generation immunotherapy product candidates in pre-clinical and clinical development for the treatment of hematological malignancies as well as solid tumors.

We are a passionate and young team of innovative scientists and clinical experts who thrive to push forward the boundaries of modern cancer therapy.


Fully addressing the limitations of current T-Cell-based therapies through our proprietary next generation ATAC, UniCAR and RevCAR platforms.

GEMoaB_Website_Icons-03_Zeichenfläche 1 Kopie.png

Broad pre-clinical and clinical stage pipeline with four assets planned to be in clinical development in solid tumors and hematological malignancies by the end of 2019; highly productive research engine with two additional investigational new drugs for our UniCAR/RevCAR platform expected within the next 18 months.


Proven expertise in manufacturing cellular immunotherapies through our sister company CELLEX, a world leader in blood stem cell products mastering all aspects of cell therapy including harvest, manipulation, expansion, scheduling and logistics.